Wedbush Reiterates Neutral on Apellis Pharmaceuticals, Maintains $29 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Laura Chico has reiterated a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained a $29 price target.
August 23, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst Laura Chico reiterated a Neutral rating on Apellis Pharmaceuticals and maintained a $29 price target.
The news is directly about Apellis Pharmaceuticals and its rating by Wedbush. The neutral rating suggests that the analyst does not expect significant price movement in the short term. The maintained price target indicates that the analyst's valuation of the company has not changed.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100